4 research outputs found
Lipoprotein (a) profile in HIV-1 infected patients treated with highly active antiretroviral therapy (HAART)
Lipoprotein (a) [Lp(a)] is recognized as an independent factor of
arteriosclerosis. The aim of this study was to appreciate the profile
of Lipoprotein (a) recognized as an independent factor of
arteriosclerosis in the monitoring of HIV-infected patients receiving
Nevirapine (NVP) regimens, an antiretroviral known to reduce
cardiovascular disease risk. The study population (136 subjects)
comprise of 106 HIV-infected subjects, and 30 HIV-negative individuals.
The 106 HIV-infected subjects were divided into groups as follows.
HAART-untreated (27), HIV-infected subjects that did not receive
antiretroviral treatment; HAART-6M (36), HIV-infected subjects on
antiretroviral treatment for six months; and HAART-12M (43),
HIV-infected subjects on antiretroviral treatment for twelve months.
All recruited patients had normal blood lipids values (Total
cholesterol < 5.2 mmol/L, Triglycerides < 2 g/L, HDLc > 0.9
mmol/L). The Lp(a) levels were significantly higher in the HIV-infected
group compared to the control (p = 0.0036). Within the HIV-infected
subjects, Lp(a) level was found to be higher in HAART-treated group
compared to HAART naive group (p=0.004). Infected subjects on the
antiretroviral treatment for12 months had higher Lp(a) levels than
those treated for 6 months (p=0.034). This study shows that adequate
management of metabolic abnormalities of HAART-treated HIV-infected
patients must include periodic measurement of Lp(a) levels
Lipoprotein (a) profile in HIV-1 infected patients treated with highly active antiretroviral therapy (HAART)
Lipoprotein (a) [Lp(a)] is recognized as an independent factor of
arteriosclerosis. The aim of this study was to appreciate the profile
of Lipoprotein (a) recognized as an independent factor of
arteriosclerosis in the monitoring of HIV-infected patients receiving
Nevirapine (NVP) regimens, an antiretroviral known to reduce
cardiovascular disease risk. The study population (136 subjects)
comprise of 106 HIV-infected subjects, and 30 HIV-negative individuals.
The 106 HIV-infected subjects were divided into groups as follows.
HAART-untreated (27), HIV-infected subjects that did not receive
antiretroviral treatment; HAART-6M (36), HIV-infected subjects on
antiretroviral treatment for six months; and HAART-12M (43),
HIV-infected subjects on antiretroviral treatment for twelve months.
All recruited patients had normal blood lipids values (Total
cholesterol 0.9
mmol/L). The Lp(a) levels were significantly higher in the HIV-infected
group compared to the control (p = 0.0036). Within the HIV-infected
subjects, Lp(a) level was found to be higher in HAART-treated group
compared to HAART naive group (p=0.004). Infected subjects on the
antiretroviral treatment for12 months had higher Lp(a) levels than
those treated for 6 months (p=0.034). This study shows that adequate
management of metabolic abnormalities of HAART-treated HIV-infected
patients must include periodic measurement of Lp(a) levels
Antiretroviral treatment and quality of life in Africans living with HIV: 12-month follow-up in Burkina Faso.
International audienceIntroduction: The scale-up of highly active antiretroviral therapy (HAART) has led to a significant improvement in survival of the HIV-positive patient but its effects on health-related quality of life (HRQOL) are less known and context-dependent. Our aim was to assess the temporal changes and factors associated with HRQOL among HIV-positive adults initiating HAART in Burkina Faso. Methods: HIV-positive people initiating HAART were prospectively included and followed over a one-year period in three HIV clinics of Ouagadougou. HRQOL was assessed at baseline and at each follow-up visit using physical (PHS) and mental (MHS) summary scores derived from the Medical Outcome Study 36-Item short-form health survey (MOS SF-36) questionnaire. Toxicity related to HAART modification and self-reported symptoms were recorded during follow-up visits. Determinants associated with baseline and changes in both scores over a one-year period were assessed using a mixed linear model. Results: A total of 344 patients were included. Their median age at baseline was 37 years [interquartile range (IQR) 30-44] and their median CD4 count was 181 cells/mm(3) (IQR 97-269). The mean [standard deviation (SD)] PHS score increased from 45.4 (11.1) at baseline to 60.0 (3.1) at 12 months (p < 10(-4)) and the mean (SD) MHS score from 42.2 (8.7) to 43.9 (3.4) (p<10(-2)). After one year of treatment, patients that experienced on average two symptoms during follow-up presented with significantly lower PHS (63.9) and MHS (43.8) scores compared to patients that presented no symptoms with PHS and MHS of 68.2 (p<10(-4)) and 45.3 (p<10(-3)), respectively. Discussion: The use of HAART was associated with a significant increase in both physical and mental aspects of the HRQOL over a 12-month period in this urban African population. Perceived symptoms experienced during follow-up visits were associated with a significant impairment in HRQOL. The appropriate and timely management of reported symptoms during the follow-up of HAART-treated patients is a key component to restore HRQOL